Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com
Debate Continues Between Primary Debulking and Neoadjuvant Chemo in Advanced Ovarian Cancer
May 31st 2019Stephen J. Lee, MD, discusses the trials that have added to existing controversies regarding the optimal management of patients with newly diagnosed advanced ovarian cancer and highlights best practices for deciding between the approaches.
Read More
Small Molecule Shows Marked Activity Against Ibrutinib-Resistant MCL
May 17th 2019Preclinical data suggest that the small molecule IACS-10759, which targets the oxidative phosphorylation (OXPHOS) and glutaminolysis pathways, may play a critical role in overcoming resistance to ibrutinib (Imbruvica) in mantle cell lymphoma.
Read More
Vaccine Shows Signs of Stimulatory Effects in Early-Stage CRC
May 8th 2019A vaccine targeting GUCY2C, a commonly overexpressed protein in patients with early-stage colorectal cancer, induced antibody and T-cell responses toward the specified target and demonstrated an acceptable safety profile in this patient population
Read More
Antidiarrheal Prophylaxis Optimizes Neratinib Use in HER2+ Breast Cancer
May 7th 2019Martin Dietrich, MD, PhD, discusses ways of offsetting neratinib-associated diarrhea for patients with early-stage HER2-positive breast cancer at high risk of recurrence in need of extended adjuvant therapy.
Read More
Chemoimmunotherapy Combos Solidified as Frontline Standard in Nonsquamous NSCLC
May 3rd 2019The rationale for frontline chemoimmunotherapy in stage IV nonsquamous non–small cell lung cancer, now made evident by several phase III trials, stems from its synergistic activity, stimulatory effects on neoantigens, and tolerable safety profile.
Read More
Clinical Factors in MCL Successful in Guiding Watch-and-Wait Strategy
April 18th 2019Although biological criteria carry prognostic value in mantle cell lymphoma, initial observation based solely on clinical criteria was found to be an effective management strategy that did not compromise patient outcomes.
Read More